US Bancorp DE Acquires 110,680 Shares of Kenvue Inc. (NYSE:KVUE)

US Bancorp DE boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 66.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 276,134 shares of the company’s stock after purchasing an additional 110,680 shares during the quarter. US Bancorp DE’s holdings in Kenvue were worth $5,896,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Alerus Financial NA boosted its position in shares of Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after acquiring an additional 491 shares during the last quarter. Kiley Juergens Wealth Management LLC lifted its stake in Kenvue by 1.9% in the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after purchasing an additional 500 shares in the last quarter. Principle Wealth Partners LLC lifted its stake in Kenvue by 3.7% in the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after purchasing an additional 500 shares in the last quarter. White Pine Capital LLC boosted its holdings in shares of Kenvue by 1.0% during the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock valued at $1,165,000 after purchasing an additional 542 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators grew its position in shares of Kenvue by 29.0% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock valued at $54,000 after purchasing an additional 568 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Down 1.5 %

Shares of KVUE opened at $23.44 on Wednesday. The firm has a fifty day moving average price of $21.54 and a 200-day moving average price of $22.30. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $44.79 billion, a P/E ratio of 44.22, a P/E/G ratio of 2.62 and a beta of 1.45. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.50%. Kenvue’s payout ratio is presently 154.72%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on KVUE shares. Piper Sandler increased their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Canaccord Genuity Group cut their target price on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a report on Friday, February 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Barclays dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. Finally, Citigroup decreased their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $23.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.